The FIREFLY-1 Trial
FIREFLY-1 is a phase 2, multicenter, open-label study to evaluate the safety and efficacy of an investigational, oral, pan-RAF inhibitor tovorafenib in pediatric patients with RAF-altered, recurrent or progressive low-grade glioma and advanced solid tumors
Sponsor: Day One Biopharmaceuticals, Inc.
Collaborator: Pacific Pediatric Neuro-Oncology Consortium (PNOC)
Status: Currently enrolling patients
Condition: Low-grade glioma and advanced solid tumors harboring RAF alterations
Phase: 2
NCT Number: NCT04775485
EudraCT Number: 2020-003657-30
Other Study ID Numbers: PNOC026
Discover more details and enrollment information about FIREFLY-1
VIEW FIREFLY-1 TRIAL
FIREFLY-1 Trial Sites
Trial sites are currently active in the following locations
VIEW TRIAL LOCATIONS